Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users

François Laliberté · Michel Cloutier · Concetta Crivera · Winnie W. Nelson · William H. Olson · Jeffrey Schein · Julie Vanderpoel · Guillaume Germain · Patrick Lefebvre

To view enhanced content go to www.advancesintherapy.com
Published online: April 17, 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

The authors wish to notify the readers that although the above mentioned article addressed different research questions and therefore evaluated different endpoints, the study employed a similar study design using the same sample of patients with nonvalvular atrial fibrillation (NVAF) treated with either rivaroxaban or warfarin as the study sample reported in a study published in Clinical Therapeutics by the present authors [1]. The current research focused on the economic evaluation of the effect of rivaroxaban versus warfarin among matched cohorts. Because the two articles were accepted for publication at the same time, the authors want to cross-reference both articles in the current addendum for clarity and transparency.

Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

REFERENCE

1. Laliberté F, Cloutier M, Crivera C, et al. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users. Clin Ther. 2015;37(3):554–62.